← Back to patent-cliff list
Vincristine Sulfate Liposome
Tier C — Watch / tradeVincristine Sulfate Liposome
Acrotech Biopharma Llc
Originator
2012
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Tubulin
Brand：Marqibo Kit
Indications (approved)：Acute lymphoblastic leukaemia, 睾丸肿瘤, Cervical cancer, Melanoma, Lymphoma, Ovarian cancer, Chronic lymphocytic leukaemia, Breast cancer
Regional status
US
Withdrawn
EU
-
China
Phase III
2014-05-07
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Vincristine Sulfate Liposome?
Approved indications include: Acute lymphoblastic leukaemia, 睾丸肿瘤, Cervical cancer, Melanoma, Lymphoma, Ovarian cancer, Chronic lymphocytic leukaemia, Breast cancer.
When does the Vincristine Sulfate Liposome patent expire?
No public expiry year is available for Vincristine Sulfate Liposome yet; this page updates once verified.
How do I get a quote for Vincristine Sulfate Liposome intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12